3M Drug Delivery Systems has introduced a new device to help control increasing costs of respiratory disease.


The 3M Intelligent Control Inhaler provides accurate doses to patients, and offer on-screen instructions for use and feedback to the patient and health care provider through an app.

The device has several features that provide opportunities to enhance outcomes by decreasing patient variability and errors, and offer information on use to health care providers and payers

A combination of breath actuation with new technology will control inspiratory flow rate and reduces errors in technique. It also provides higher level of consistency of drug delivery between breaths and between patients.

The inhaler’s patient-proof design helps in removing critical errors in use, as well as minimizing the resources for training patients in accurate inhalation technique.

The dose is registered when the patient correctly inhales medication rather than on actuation of the device, delivering accurate information for the patient.

Intelligent Control inhaler uses a data management platform to record device usage and inspiration profiles for monitoring disease progression and providing treatment decisions.

3M Drug Delivery Systems global marketing operations manager Louise Righton said: "Providing an effective and intuitive delivery method for respiratory disease treatment is critical to patients, health care providers and payers alike.

"Poor technique in using an inhaler, coupled with the challenges of getting patients to adhere to their medication protocols, can lead to exacerbations, increased use of health care resources and ultimately, a burden on health care systems."

The device, which 3M will develop in partnership with a pharmaceutical firm, is anticipated to be in use by the end of 2020.

Image: 3M Drug Delivery Systems’ new Intelligent Control inhaler. Photo: courtesy of 3M.